BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis

[1]  Chung-Yi Li,et al.  BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies , 2021, Medicina.

[2]  H. Rugo,et al.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer , 2021, Targeted Oncology.

[3]  Shanyang He,et al.  PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival , 2021, Aging.

[4]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[5]  Y. Kamatani,et al.  Population-based Screening for Hereditary Colorectal Cancer Variants in Japan. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  A. Kilic,et al.  Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls , 2020, International journal of cancer.

[7]  H. Redmond,et al.  Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta‐analysis , 2020, The British journal of surgery.

[8]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[9]  D. Slade.  PARP and PARG inhibitors in cancer treatment. , 2020, Genes & development.

[10]  R. Eeles,et al.  Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆ , 2020, European urology.

[11]  A. Maitra,et al.  PARP inhibition — opportunities in pancreatic cancer , 2019, Nature Reviews Clinical Oncology.

[12]  Y. You,et al.  ASO Author Reflections: Toward Molecularly-Driven Personalized Care for Young Adults with Rectal Cancer , 2019, Annals of Surgical Oncology.

[13]  A. Tutt,et al.  A decade of clinical development of PARP inhibitors in perspective , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Li Fang,et al.  Detection of DNA base modifications by deep recurrent neural network on Oxford Nanopore sequencing data , 2019, Nature Communications.

[15]  S. Caulfield,et al.  Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation , 2019, Journal of the advanced practitioner in oncology.

[16]  L. Byers,et al.  PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers , 2019, Clinical Cancer Research.

[17]  J. Jeter,et al.  BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[18]  A. Sapino,et al.  PARP Inhibitors in Ovarian Cancer. , 2018, Recent patents on anti-cancer drug discovery.

[19]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[20]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[21]  J. Marshall,et al.  The Growing Challenge of Young Adults With Colorectal Cancer. , 2017, Oncology.

[22]  Daniele M. Gilkes,et al.  BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. , 2017, Integrative cancer science and therapeutics.

[23]  Hajime Uno,et al.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Mardis.  DNA sequencing technologies: 2006–2016 , 2017, Nature Protocols.

[25]  R. Myers,et al.  Advancements in Next-Generation Sequencing. , 2016, Annual review of genomics and human genetics.

[26]  P. Broderick,et al.  Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes , 2016, Familial Cancer.

[27]  L. Saal,et al.  Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Matei David,et al.  Nanocall: an open source basecaller for Oxford Nanopore sequencing data , 2016, bioRxiv.

[29]  L. Boardman,et al.  Clinical and molecular features of young-onset colorectal cancer. , 2016, World journal of gastroenterology.

[30]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[31]  W. Han,et al.  Unique Features of Young Age Breast Cancer and Its Management , 2014, Journal of breast cancer.

[32]  M. Salto‐Tellez,et al.  Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability , 2014, Molecular cell.

[33]  A. Venkitaraman.  Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2 , 2014, Science.

[34]  Charis Eng,et al.  Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study , 2013, British Journal of Cancer.

[35]  D. Bulavin,et al.  Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation. , 2013, Cancer cell.

[36]  Anna Jakubowska,et al.  BRCA1 mutations and colorectal cancer in Poland , 2010, Familial Cancer.

[37]  Junjie Chen,et al.  BRCA1 and its toolbox for the maintenance of genome integrity , 2010, Nature Reviews Molecular Cell Biology.

[38]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[39]  Zhanjiang Liu.  DNA Sequencing Technologies , 2007 .

[40]  Ayala Hubert,et al.  Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations , 2007, Journal of Medical Genetics.

[41]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[43]  Ronit Almog,et al.  BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. , 2004, Journal of the National Cancer Institute.

[44]  J. Satagopan,et al.  Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. , 2004, Journal of the National Cancer Institute.

[45]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[46]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[47]  E. Friedman,et al.  The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients , 2001, British Journal of Cancer.

[48]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[49]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[50]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[51]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[52]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[53]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[54]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[55]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[56]  M. Provencio,et al.  Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.